
The company reported its EPS on 9/29/2017. Currently, the stock has a 1 Year Price Target of $129.25.
The consensus recommendation, according to Zacks Investment research, is 1.74. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1.21 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.22 and 1.33 respectively.
Celgene Corporation on 9/29/2017 reported its EPS as $1.61 with the analysts projecting the EPS of the stock as $1.59. The company beat the analyst EPS Estimate with the difference of $0.02. This shows a surprise factor of 0.013%.
Many analysts have provided their estimated foresights on Celgene Corporation Earnings, with 27 analysts believing the company would generate an Average Estimate of $1.93.
Whereas they predicted High and Low Earnings Estimate as $2.03 and $1.87 respectively. While in the same Quarter Previous year, the Actual EPS was $1.61.
Analysts are also projecting an Average Revenue Estimate for Celgene Corporation as $3.46 Million in the Current Quarter. This estimate is provided by 25 analysts.
The High Revenue estimate is predicted as 3.62 Million, while the Low Revenue Estimate prediction stands at 3.34 Million. The company’s last year sales total was 2.98 Million.
For the Current Quarter, the growth estimate for Celgene Corporation is 19.9%, while for the Next Quarter the stock growth estimate is 19.6%.
In the past 5 years, the stock showed growth of 24.81% per annum. While for the next 5 years, the growth estimate is 20.72%.
Insider Trades for Celgene Corporation show that the latest trade was made on 25 Oct 2017 where Hugin (Robert J), the Officer and Director completed a transaction type “Buy” in which 2020 shares were traded at a price of $49.48.
Celgene Corporation (CELG) has the market capitalization of $78.23 Billion. The company rocked its 52-Week High of $147.17 and touched its 52-Week Low of $94.55.
The stock has Return on Assets (ROA) of 13.3 percent. Return on Equity (ROE) stands at 48.7% and Return on Investment (ROI) of 11.7 percent.
The stock is currently showing YTD performance of -15.19 Percent. The company has Beta Value of 1.84 and ATR value of 4.95. The Weekly and Monthly Volatility stands at 4.07% and 2.36%.
Source: factsreporter
No comments:
Post a Comment